Vincristine and asparaginase combined with prednisolone could make a positive role on the ALL patients, but probably increased the early event risk on resistant patients.[10] When using vincristine and prednisone, ALL patients’ event-free survival was improved.[11] In a study, the ALL patients received asparaginase greater than 26 weeks had a better outcome than those who tolerated 25 weeks or fewer, which means the effect of asparaginase may have a positive correlation with using duration.[12] However, different studies enrolled different sample, and research design are in difference either. The gene discussed is ASPG; the disease is acute lymphoblastic leukemia.